SVFCX vs. MANH, TTAN, PCTY, NICE, PCOR, KVYO, DSGX, ALTR, ESTC, and DAY
Should you be buying Smead Value C stock or one of its competitors? The main competitors of Smead Value C include Manhattan Associates (MANH), ServiceTitan (TTAN), Paylocity (PCTY), NICE (NICE), Procore Technologies (PCOR), Klaviyo (KVYO), The Descartes Systems Group (DSGX), Altair Engineering (ALTR), Elastic (ESTC), and Dayforce (DAY). These companies are all part of the "computer and technology" sector.
Smead Value C vs.
Smead Value C (NASDAQ:SVFCX) and Manhattan Associates (NASDAQ:MANH) are both computer and technology companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, community ranking, risk, institutional ownership, profitability, earnings, media sentiment, dividends and valuation.
In the previous week, Manhattan Associates had 28 more articles in the media than Smead Value C. MarketBeat recorded 28 mentions for Manhattan Associates and 0 mentions for Smead Value C. Manhattan Associates' average media sentiment score of 1.05 beat Smead Value C's score of 0.00 indicating that Manhattan Associates is being referred to more favorably in the news media.
Smead Value C has a beta of 0.11, suggesting that its stock price is 89% less volatile than the S&P 500. Comparatively, Manhattan Associates has a beta of 1.13, suggesting that its stock price is 13% more volatile than the S&P 500.
Manhattan Associates has a net margin of 20.95% compared to Smead Value C's net margin of 0.00%. Manhattan Associates' return on equity of 84.62% beat Smead Value C's return on equity.
Manhattan Associates has a consensus target price of $210.14, suggesting a potential upside of 12.08%. Given Manhattan Associates' stronger consensus rating and higher probable upside, analysts plainly believe Manhattan Associates is more favorable than Smead Value C.
60.2% of Smead Value C shares are owned by institutional investors. Comparatively, 98.4% of Manhattan Associates shares are owned by institutional investors. 10.3% of Smead Value C shares are owned by company insiders. Comparatively, 0.9% of Manhattan Associates shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Manhattan Associates has higher revenue and earnings than Smead Value C.
Manhattan Associates received 532 more outperform votes than Smead Value C when rated by MarketBeat users. However, 100.00% of users gave Smead Value C an outperform vote while only 63.50% of users gave Manhattan Associates an outperform vote.
Summary
Manhattan Associates beats Smead Value C on 13 of the 15 factors compared between the two stocks.
Get Smead Value C News Delivered to You Automatically
Sign up to receive the latest news and ratings for SVFCX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
SVFCX vs. The Competition
Smead Value C Competitors List
Related Companies and Tools
This page (NASDAQ:SVFCX) was last updated on 5/23/2025 by MarketBeat.com Staff
Buy SVFCX Stock Free SVFCX Stock Alerts